<DOC>
	<DOCNO>NCT01664754</DOCNO>
	<brief_summary>This phase I trial study side effect best dose exemestane combination pemetrexed disodium carboplatin treat post-menopausal woman stage IV non-small cell lung cancer . Exemestane may stop growth tumor call block enzyme need cell growth . Drugs use chemotherapy , pemetrexed disodium carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving exemestane together pemetrexed disodium carboplatin may kill tumor cell</brief_summary>
	<brief_title>Exemestane , Pemetrexed Disodium , Carboplatin Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Evaluate safety tolerability escalate dos exemestane give pemetrexed ( pemetrexed disodium ) carboplatin post-menopausal woman stage IV non-squamous , non-small cell lung cancer ( NSCLC ) . SECONDARY OBJECTIVES : I . Determine objective tumor response rate ( define Response Evaluation Criteria Solid Tumors [ RECIST ] 1.1 ) patient treat pemetrexed , carboplatin exemestane . II . Evaluate pharmacokinetic profile pemetrexed , carboplatin exemestane . III . Evaluate quality life patient treat pemetrexed , carboplatin exemestane . IV . Analyze tumor tissue biomarkers potential correlation response . OUTLINE : This dose-escalation study exemestane . Patients receive exemestane orally ( PO ) daily ( QD ) day 1-28 pemetrexed disodium intravenously ( IV ) 15 minute carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day , every 3 month thereafter .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) Histologically cytologically confirm , treatmentnaive ( status post single treatment regimen tyrosine kinase inhibitor single agent ) stage IV nonsquamous , NSCLC Measurable disease accord modify RECIST version 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 Expected survival time &gt; = 3 month opinion investigator Postmenopausal woman ; woman eligible postmenopausal ( old 50 year age spontaneous menses least 12 month ; 50 year age young either spontaneous menses [ amenorrheic ] within 12 month randomization [ e.g. , spontaneous secondary hysterectomy ] folliclestimulating hormone level within postmenopausal range prior bilateral oophorectomy ) Ability provide formalinfixed , paraffinembedded ( FFPE ) tumor tissue sample contain representative tumor tissue previously obtain biopsy/resection meet specific tissue sample requirement screen History another primary cancer within 3 year prior day 1 exception curatively treat skin cancer ( melanoma ) curatively treated cervical carcinoma insitu Untreated central nervous system ( CNS ) involvement ; ( treat CNS involvement permit patient currently steroid therapy remain stable , unchanged dose steroid &gt; = 3 week ) Recent major surgery within prior 4 week ; ( mediastinoscopy placement central venous access allow long placement 7 day prior receive study drug ) Any prior concurrent investigational standard therapy treatment metastatic NSCLC include radiation therapy , chemotherapy , biological therapy ( exception single treatment regimen tyrosine kinase inhibitor single agent , must complete 28 day prior day 1 ) , hormonal therapy , immunotherapy ; ( palliativetargeted radiotherapy brain bone metastasis permit provide least 14 day prior day 1 ) History hormone replacement therapy ( estrogens without progestin ) aromatase inhibitor ( anastrazole , letrozole , exemestane ) within 8 week prior day 1 Osteoporosis complicate pathologic fracture Concurrent investigational agent nonmalignant disease prior investigational agent nonmalignant disease within 4 week 5 halflives ( whichever short ) prior day 1 Concurrent cytotoxic immunosuppressive therapy nonmalignant disease ( e.g. , rheumatoid arthritis lupus ) Absolute neutrophil count ( ANC ) &lt; 1500/mL Platelet count &lt; 100,000/mL Hemoglobin &lt; 9.0 g/dL Serum bilirubin &gt; 1.5 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 x ULN ( AST ALT &gt; 5 x ULN subject liver metastasis ) Glomerular filtration rate ( GFR ) = &lt; 50 Albumin = &lt; 2.5 g/dL Known history positive test result human immunodeficiency virus ( HIV ) Active infection ( include HIV/acquired immune deficiency syndrome [ AIDS ] , hepatitis B , hepatitis C infection ) require systemic antibiotic , antiviral , antifungal History myocardial infarction within 12 month prior day 1 clinically significant coronary disease New York Heart Association grade II great congestive heart failure Unstable coronary disease clinically significant electrocardiogram ( ECG ) ( 12lead ) abnormality , determine investigator Inability comply study followup procedures Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find lead reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render subject high risk treatment complication Other unspecified reason , opinion investigator sponsor , make subject unsuitable enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>